Jafron Biomedical Co (SZSE:300529) ROCE % : 27.02% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jafron Biomedical Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 27.02%.

Jafron Biomedical Co ROCE % Historical Data

The historical data trend for Jafron Biomedical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co ROCE % Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

33.49

39.53

38.68

23.08

12.22

Jafron Biomedical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															15.78	3.08	30.43	29.58	27.02

Jafron Biomedical Co ROCE % Calculation

Jafron Biomedical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	575.353	/	( ( (5416.543 - 717.182)	+	(5543.302 - 829.42) )	/ 2 )
	=	575.353	/	( (4699.361	+	4713.882)	/ 2 )
	=	575.353	/	4706.6215
	=	12.22 %

Jafron Biomedical Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	1239.012	/	( ( (5458.201 - 1008.9)	+	(5593.126 - 872.869) )	/ 2 )
	=	1239.012	/	( ( 4449.301	+	4720.257 )	/ 2 )
	=	1239.012	/	4584.779
	=	27.02 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Jafron Biomedical Co (SZSE:300529) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jafron Biomedical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co Headlines

No Headlines